Published: May 8, 2018

Introduction {#sec1}
============

Hematopoietic stem cell (HSC) transplants are the only globally adopted stem cell therapy for patients and have been shown to be curative for hematological malignancies and diseases along with certain solid tumors ([@bib8]). However, given the scarcity of compatible donors against the number of patients in need ([@bib18]), developing alternative sources of HSCs is paramount. While hematopoietic progenitor cells (HPCs) can readily be generated by human pluripotent stem cells (hPSCs) *in vitro*, they lack robust engraftment potential ([@bib17], [@bib26], [@bib29], [@bib32], [@bib44]). Ectopic transcription factor (TF) expression has been used in attempts to induce bone marrow (BM) engraftment of hPSC-HPCs ([@bib13], [@bib12], [@bib30], [@bib31], [@bib44]). Recently, expression of seven TFs in hPSC-derived hemogenic endothelium generated HSC/HPCs, but only after BM transplantation ([@bib37]). Despite this progress, the *in*-*vivo*-dependent approach did not produce an abundance of HSCs and these cells remain molecularly unrelated to somatic HSCs---factors that require modification for successful clinical translation.

Unlike solid organ transplants, injected HSCs must migrate to and reside in specialized niches in the BM, the primary site of adult hematopoiesis ([@bib2]). Adult HSCs receive complex and dynamic cues from the BM for survival, quiescence, homeostasis, and proliferation. Likewise, using co-cultures of BM stroma cells or embryonic niche cells improves hPSC-HPC derivation ([@bib25], [@bib41], [@bib43], [@bib46]), suggesting these cells too require specific niche cues. BM secreted CXCL12 (formerly known as SDF1) is a powerful regulator of HSC function and binds its cognate receptor, CXCR4, expressed by HSC/HPCs ([@bib24], [@bib27], [@bib38]). CXCR4 represents the sole chemokine receptor utilized by HSCs for migration/chemotaxis ([@bib47]) and regulates the proliferation of somatic HSCs ([@bib23]). This is sustained through an auto-regulatory loop that is dynamically regulated from cell surface to intracellular stores ([@bib24]). CXCR4 is regulated by BM factors, some of which include hypoxia ([@bib36]), Notch ([@bib45]), glucocorticoid ([@bib19]), and prostaglandin E~2~ (PGE~2~) ([@bib16]) signaling pathways. However, the functional capacity of hPSC-HPCs to respond to BM regulatory cues remains largely unknown.

Previous studies assessing hPSC-HPC engraftment potential have reported low levels of human hematopoietic microchimerism in immunocompromised mouse BM 4 weeks or more post transplant ([@bib13], [@bib12], [@bib17], [@bib26], [@bib30], [@bib31], [@bib32], [@bib44]). Here, we reveal the previously unappreciated early transplantation failure of hPSC-HPCs *in vivo* that occurs within the first 24 hr, despite robust hematopoietic progenitor capacity detected for weeks *in vitro*. Across a broad range of differentiation methodologies, global transcriptional analysis identified the chemokine receptor CXCR4 as aberrantly regulated in hPSC-HPCs. Molecular and biochemical characterization of ectopic CXCR4 in hPSC-HPCs demonstrated that CXCR4 enhances survival and progenitor retention following BM transplantation. We propose the CXCR4 network is essential for physiological responsiveness toward generating *bona fide* HSCs from hPSCs.

Results {#sec2}
=======

Defective *In Vivo* Retention of hPSC-HPCs {#sec2.1}
------------------------------------------

Early properties of hPSC-HPC integration into the BM *in vivo* have not been explored by direct side by side comparisons with human adult/somatic HPC sources. Cord blood (CB) is readily available for experimentation as a somatic source of HSCs that establish long-term multilineage hematopoietic engraftment in xenograft models ([@bib3]). Furthermore, transplantation of CB cells has been used clinically for long-term reconstitution of donor-derived healthy hematopoiesis in patients ([@bib10]). As such, we used CB as a source of transplantable cells to analyze early HPC behavior and compare this directly with HPCs derived from hPSCs. hPSC-derived HPCs were derived using embryoid body (EB) formation and differentiated with hematopoietic cytokines and BMP4 ([@bib7]), and were utilized on EB day 15 for analysis and transplantation. Somatic and hPSC-HPCs do not share equivalent frequencies of phenotypic or functional progenitors, as quantified by human specific CD34^+^CD45^+^ cell surface expression (versus mouse mCD45; [Figure 1](#fig1){ref-type="fig"}A) and colony forming unit (CFU) composition ([Figure S1](#mmc1){ref-type="supplementary-material"}A), respectively. These results are consistent with previous reports across a broad range of methodologies to produce phenotypic or functional progenitors from hPSCs ([@bib13], [@bib26], [@bib30], [@bib32], [@bib35], [@bib41], [@bib43]), as well as non-human primate *Macaca nemestrina*-induced PSC-derived HPCs ([@bib17]). To accurately control for the number of input human CD34^+^CD45^+^ cells and functional progenitors injected from hPSC-HPC cultures, we therefore selected two doses of CB for transplantation ([Figure 1](#fig1){ref-type="fig"}B). The higher CB dose, CB^CD34^, closely approximates the number of total phenotypic hPSC-HPCs transplanted (dark red, 5 × 10^4^ CD34^+^ cells). The lower dose, CB^PRO^, closely approximates the total number of functional hPSC-HPC progenitors, as well as the clinical dose of 2 × 10^5^ CD34^+^ cells/kg ([@bib15]) when scaled by mass to a 25 g mouse (light red, 5 × 10^3^ CD34^+^ cells). Total phenotypic and functional HPCs prior to injection were measured at day 0 ([Figures 1](#fig1){ref-type="fig"}A and 1B).Figure 1Transplantation Kinetics of Somatic and hPSC-Derived HPCs(A) Phenotype of CB and hPSC-derived HPCs in injection fraction (human CD34^+^ human CD45^+^ mouse CD45^--^), analyzed on the day of transplant. Mouse CD45 antibody use validated to exclude mouse cells upon BM transplantation.(B) Total viable cells, and total phenotypic (CD34^+^CD45^+^) and functional (CFU) CB and hPSC-derived HPCs in injection fraction, analyzed on the day of transplant. CB^CD34^ and CB^PRO^ cell doses control for input phenotypic and functional hPSC-HPCs, respectively. Data points represent the transplanted cells of three independent transplants. Data are represented as means ± SEM.(C) Tissue allocation for phenotypic and functional assays.(D) *n* numbers represent transplanted mice, pooled from three independently performed experiments with six harvest analyses.(E) Phenotype of CB and hPSC-derived HPCs from harvested BM.(F) Total mCD45^--^hCD45^+^CD34^+^ cells retained in the BM of injected (IF) and contralateral (CF) femurs. To assess BM retention separately from proliferation, only 24 and 48 hr data for CB shown. Data points represent *n* transplanted mice, Ø is zero. Two-way ANOVA, ^∗∗∗∗^p \< 0.0001. Data are represented as means ± SEM.(G and H) Total mCD45^--^hCD45^+^CD34^+^ cells per injected femur. Same hPSC-HPC data in both panels.(I) CFU from CB-transplanted BM, harvested at day 5. Arrowheads: red, burst-forming unit-erythroid; gray, CFU-granulocyte and/or -monocyte.(J) Total human CFU per harvested IF and CF BM. To assess BM retention of progenitors separately from cellular proliferation and expansion, only 24 and 48 hr retention data for CB shown; day 3 and 5 data omitted. Data points represent *n* transplanted mice, Ø is zero. One-way ANOVA, ^∗∗^p \< 0.01. Data are represented as means ± SEM.(K and L) Total human CFU per IF. Same hPSC-HPC data in both panels.(M) Linear regression of total CB phenotypic versus functional HPCs quantified per IF. Data points represent *n* transplanted mice.

Using this carefully quantitated approach to phenotypically and functionally enumerate equivalency of transplanted cells, human CB versus hPSC-derived HPCs were injected into the femurs of murine recipients, where the BM was assessed for human chimerism at the functional and phenotypic level at multiple time points within the first week. At the same time points as injected femur assessment, we determined migration capacity *in vivo* by analysis of contralateral femur BM, spleen, and lungs ([Figure 1](#fig1){ref-type="fig"}C). The number of individual mice from four transplant groups were compared at 24 hr and 2, 3, and 5 days as indicated ([Figure 1](#fig1){ref-type="fig"}D) to address the classical time of homing, within 24 hr ([@bib22]), while also being inclusive of longer periods of homing, up to 4 days ([@bib14]). The frequency of human hematopoietic cell chimerism was rare, but could be captured by flow cytometric analysis for human HPCs (mCD45^--^hCD45^+^CD34^+^, [Figures 1](#fig1){ref-type="fig"}E, [S1](#mmc1){ref-type="supplementary-material"}B, and S1C). Phenotypic CB HPC expansion was evident within the injected femur BM well within this time frame ([Figure 1](#fig1){ref-type="fig"}E). As predicated ([@bib44]), intra-femoral injection provided an engraftment advantage to retain HPCs in the injected femur, while a subpopulation of somatic HPCs could still home to the contralateral femur ([Figure 1](#fig1){ref-type="fig"}F) but not to extramedullary sites such as the lung ([Figures S1](#mmc1){ref-type="supplementary-material"}D--S1F) or spleen ([Figures S1](#mmc1){ref-type="supplementary-material"}G--S1I). In contrast, hPSC-HPCs were not able to persist even at 24 hr post transplant in any location, yet CB HPCs were capable of robust and exponential expansion in the BM at both cellular doses ([Figures 1](#fig1){ref-type="fig"}G and 1H; comparison of fits test, Prism software). Due to the rarity of these cells at early time points post transplantation, evaluation of HSC function by secondary transplantation was not feasible for both somatic and hPSC-derived HPCs. However, we were able to extract BM and compare early engraftment kinetics at the progenitor level using the CFU assay *in vitro*. Functional CB HPCs were retained in injected femur BM and continued progenitor output over the first week, while putative hPSC-HPCs failed to be retained as measured by erythroid-myeloid CFU assays ([Figures 1](#fig1){ref-type="fig"}J--1L). Strikingly, BM retention of CB HPCs was strongly correlated between phenotypic and functional measures, whereas no such relationship existed for hPSC-HPCs ([Figure 1](#fig1){ref-type="fig"}M). These results suggest a reduction of somatic HPCs within the first 24 hr post injection, followed by a rapid increase from 24 hr to 5 days *in vivo*. This behavior is in sharp contrast with hPSC-HPCs, which fail to recover and proliferate *in vivo*. These experimental observations reveal an unappreciated deficiency contributing to hPSC-HPC engraftment failure that occurs upon initial transplantation.

Somatic and hPSC-Derived HPCs Are Functionally Similar *In Vitro* {#sec2.2}
-----------------------------------------------------------------

Based on the inability of hPSC-HPCs to survive and proliferate *in vivo*, we examined their behavior *in vitro* across a broad range of hPSC differentiation methodologies, and compared them with adult/somatic control sources of HPCs. Somatic HPCs can be harvested from human BM, adult mobilized peripheral blood (MPB), and neonatal CB sources, and are enriched in the CD34^+^CD45^+^ subpopulation ([Figure 2](#fig2){ref-type="fig"}A). Similarly, the past decade has provided several methodologies to derive hPSC-HPCs, and so we investigated three very different protocols and approaches: (1) cytokines and BMP4 treatment of EBs ([@bib7]), (2) OP9 co-culture ([@bib43]), and (3) endothelial-hematopoietic transition (EHT) ([@bib26]) ([Figure 2](#fig2){ref-type="fig"}B). We routinely observed hPSC-derived hematopoietic CFU morphology similar to somatic HPCs when cultured for 14 days *in vitro* ([Figures 2](#fig2){ref-type="fig"}C and 2D). To control for variations in CD34^+^CD45^+^ frequency, we determined the CFU output and lineage distribution per 1,000 CD34^+^CD45^+^ cells, which was similar across adult BM, adult MPB, and neonatal CB donor samples ([Figure 2](#fig2){ref-type="fig"}E). Similarly, while the three differentiation methods produced varying frequencies of hPSC-HPCs ([Figure 2](#fig2){ref-type="fig"}B), CFU per 1,000 HPCs was also similar ([Figure 2](#fig2){ref-type="fig"}F). hPSC-HPCs readily survive and proliferate *in vitro* ([Figure 2](#fig2){ref-type="fig"}) and yet failed to survive very short time frames *in vivo* ([Figure 1](#fig1){ref-type="fig"}). Even the same hPSC-HPCs tested in parallel in these two environments (*in vivo* versus *in vitro*) led to sharply contrasting effects in progenitor capacity ([Figures 1](#fig1){ref-type="fig"}B and 1K). These comparative results indicate hPSC-HPCs may be insufficiently responding to BM environmental cues *in vivo* that prevent the survival that can be readily demonstrated *in vitro*.Figure 2Shared Progenitor Capacity of Somatic and hPSC-Derived HPCs(A) Phenotypic (CD34^+^CD45^+^) somatic HPCs, by flow cytometry. Negative stain in black.(B) Phenotypic (CD34^+^ with CD45^+^ and/or CD43^+^) hPSC-HPCs, by flow cytometry, with: cytokines and BMP4 ([@bib7]); OP9 co-culture ([@bib43]); and EHT in normoxia or hypoxia ([@bib26]) differentiation methods. Negative stain in black.(C and D) Somatic (C), and hPSC-derived (D) hematopoietic colonies (CFU); picked CFU were spun onto slides for Wright-Giemsa staining (Cytospin). White scale bar represents 500 μm; black scale bar represents 30 μm.(E and F) Total CFU relative to 1.0 × 10^3^ input phenotypic HPCs from (E) somatic HPCs; data points represent *n* = 4 (BM, CB) and *n* = 8 (MPB) independently assayed wells, pooled from independently performed healthy donors (BM *n* = 1, CB *n* = 2, MPB *n* = 3); and (F) hPSC-HPCs; data points represent *n* = 10 (cytokines and BMP4, OP9 co-culture) and *n* = 3 (EHT, hypoxia \[hyp.\], and normoxia \[nor.\]) independently assayed wells, pooled from independently performed experiments. One-way ANOVA, no statistical differences. Data are represented as means ± SEM.BFU-E, burst-forming unit-erythroid; E, erythrocyte; G, granulocyte; GEM, granulocyte, erythrocyte, and monocyte; GM, granulocyte and monocyte; and M, monocyte.

Deficient Chemokine Receptor Expression Is a Consistent Feature of hPSC-HPCs {#sec2.3}
----------------------------------------------------------------------------

To understand potential underlying interactions that differ between hPSC-HPCs and BM versus adult/somatic HPCs and BM, we applied global transcriptome analysis of primitive hematopoietic populations enriched for HSC/HPCs (CD45^+^CD34^+^CD38^--^), from 15 healthy donors, including BM, MPB, CB, and fetal blood (FB) sources ([Figure 3](#fig3){ref-type="fig"}A, see also [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}) and collectively compared these with hPSC-HPCs-derived samples using the cytokines and BMP4 ([@bib7]), and EHT method of differentiation ([@bib26]), as well as using gene expression data for TF-expressing hPSC-HPCs ([@bib13]). Gene set enrichment analysis (GSEA) of global transcriptional profiles identified several gene sets relevant to environmental cues *in vivo*, including chemokine receptors, extracellular matrix interactions, integrins, and cell surface interactions at the vascular wall ([Figure 3](#fig3){ref-type="fig"}B, [Table S1](#mmc1){ref-type="supplementary-material"}), which were enriched in hPSC-HPCs. Closer observation identified two consistent differentially expressed chemokine receptor genes, CXCR4 and CX3CR1 ([Figure 3](#fig3){ref-type="fig"}C), which are associated with BM retention and egress, respectively ([@bib28]). We next performed global transcriptome analysis comparing the four different sources of hPSC-HPCs individually with somatic HPCs (MPB, BM, CB, and FB), which identified 666 consistently differentially expressed genes ([Figure 3](#fig3){ref-type="fig"}D, [Table S2](#mmc1){ref-type="supplementary-material"}). Unsupervised hierarchical clustering segregated 120 as exclusively expressed by somatic HPCs ([Figure 3](#fig3){ref-type="fig"}E). Within these 120 genes, we observed HOXA5, HOXA10, FLT3, and PROM1, and epigenetic regulators such as HDAC7, KAT6A, and MLLT3, as well as CXCR4, which are down-regulated in hPSC-HPCs compared with somatic HPCs ([Table S2](#mmc3){ref-type="supplementary-material"}). STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) protein-protein interaction database ([@bib40]) analysis identified potential interactions of the 120 HSC-related genes, where CXCR4 is prominently linked to key HSC/HPC-related genes ([Figure 3](#fig3){ref-type="fig"}F).Figure 3Identification of Aberrant Chemokine Receptor Expression by hPSC-HPCs(A) Principal component analysis (PCA) of global transcriptome from fluorescence-activated cell sorting (FACS)-purified CD45^+^CD34^+^CD38^±^ HPCs, including samples from GEO: GSE49938 ([@bib13]), and from our lab (GEO: GSE3823 and GSE106721), diamond and circle symbols, respectively. Further details in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.(B) Gene sets identified by GSEA as enriched in hPSC- versus somatic HPCs, using meaned groups described in [Figure 1](#fig1){ref-type="fig"}A. GSEA reports in [Table S1](#mmc2){ref-type="supplementary-material"}.(C) Blue-Pink O′ Gram heat maps from GSEA report using meaned groups described in [Figure 1](#fig1){ref-type="fig"}A.(D) ANOVA comparing the four sources of hPSC-HPCs individually with somatic HPCs, depicted as a Venn diagram.(E) Unsupervised hierarchical clustering of hPSC- and somatic HPCs using 666 genes identified in [Figure 3](#fig3){ref-type="fig"}D.(F) STRING analysis of 120 somatic HPC up-regulated genes, where 43 are shown; 77 disconnected nodes were removed.(G and H) Flow cytometry of CXCR4 and CX3CR1 of CD34^+^CD45^+^ somatic HPCs (G), and hPSC-HPCs (H); HPC phenotypes in [Figure 2](#fig2){ref-type="fig"}B. Negative stain in black.(I and J) Summary of CXCR4^+^CX3CR1^--^ (I), and CX3CR1^+^CXCR4^--^ (J), expression of phenotypic HPCs, as assessed by flow cytometry. Data points represent *n* independent healthy donors (somatic HPCs) or independent biological replicates (hPSC-HPCs) (precise *n* values indicated in the figure), pooled from independently performed experiments. Triangle symbols indicate biological replicates cultured in hypoxia. Data are represented as means ± SEM.

These consistent observations suggested a potentially broad deficiency that we further investigated with flow cytometric analysis, which revealed that CXCR4 and CX3CR1 proteins are mutually exclusively expressed on the cell surface ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S3C). Furthermore, CXCR4 is enriched on CB HPCs ([Figure S2](#mmc1){ref-type="supplementary-material"}A), while CX3CR1 is enriched on hPSC-HPCs ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). We expanded upon these observations with three diverse sources each of somatic and hPSC-derived HPCs ([Figures 3](#fig3){ref-type="fig"}G--3J). We observed a highly reproducible CXCR4^+^CX3CR1^--^ phenotype expressed by un-cultured somatic HPCs and absence of this subset from hPSC-HPCs, which instead were CX3CR1^+^CXCR4^--^. Importantly, somatic HPCs engrafted in mice at 5 weeks continued to highly express CXCR4 ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Low expression of cutaneous lymphocyte antigen (CLA, HECA452 clone) was recently suggested to have a role in hPSC-HPC transplantation deficiency ([@bib26]). While we could replicate low CLA expression relative to a somatic HPC source, we again did not observe CXCR4 expression by transcriptional or protein analyses of EHT-derived hPSC-HPCs ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F), suggesting both may be important factors. CXCR4^--^ and CX3CR1^+^ phenotypes of hPSC-HPCs have been previously noted ([@bib29], [@bib34], [@bib41]) and reinforce our observations that low CXCR4 expression is a consistent deficiency of hPSC-HPCs across a broad range of methodologies and hPSC cell lines.

To move beyond phenotypic observations, we physically isolated CB and hPSC-derived hematopoietic cells based exclusively on chemokine receptor expression, and determined biological hematopoietic progenitor function. As predicted, hematopoietic progenitors measured by CFU potential were enriched within CXCR4^+^ CB cells, and not observed from CX3CR1^+^ cells ([Figures 4](#fig4){ref-type="fig"}A--4C), as CX3CR1 expression is restricted to mature hematopoietic cells ([@bib28]). In stark contrast, CFU potential was observed from CX3CR1^+^ hPSC-derived hematopoietic cells, while CXCR4^+^ hPSC-derived cell CFU potential was significantly reduced ([Figures 4](#fig4){ref-type="fig"}D--4F). CXCR4 and CX3CR1 are chemokine receptors that bind only one cytokine: CXCL12 and CX3CL1, respectively ([@bib1]). CXCL12 is most highly expressed in BM tissue, whereas CX3CL1 is more highly expressed in non-hematopoietic and extramedullary sites such as the lungs, kidneys, and spleen ([@bib42]). We therefore sought to determine whether the CXCR4 or CX3CR1 receptors expressed by hPSC-hematopoietic cells ([Figure 3](#fig3){ref-type="fig"}E) were functionally capable of initiating chemotaxis toward their cognate ligands ([Figure 4](#fig4){ref-type="fig"}G), to investigate whether hPSC-HPCs may be receiving BM cues for retention or egress. Serving as a positive control, bulk somatic hematopoietic cells were able to migrate toward both CXCL12 and CX3CL1 ([Figure 4](#fig4){ref-type="fig"}H), as both receptors were observed on bulk CB cells ([Figure 3](#fig3){ref-type="fig"}D). MPB was an exception, which exhibited a blunted response toward CXCL12 ([Figure 4](#fig4){ref-type="fig"}H), which is likely correlated to CXCR4-antagonist treatment (AMD3100) in donors to mobilize healthy HSCs and HPCs out of the BM and into circulation ([@bib6]). Despite multiple experiments, hPSC-HPCs did not migrate toward CXCL12 or CX3CL1 ([Figure 4](#fig4){ref-type="fig"}H). *In vivo* BM engraftment requires signals mediating BM retention and limiting egress. Due to the lack of chemotactic response exhibited by hPSC-HPCs ([Figure 4](#fig4){ref-type="fig"}H), we suggest the lack of CXCL12-CXCR4 function is preventing BM retention, while CX3CL1-CX3CR1 binding is not actively participating in BM egress ([@bib28]). Together, these data suggest that promoting CXCR4 expression may be beneficial to improve hPSC-HPC function.Figure 4Differential Segregation of Progenitors by CXCR4 and CX3CR1(A) Sort purities from CB cells FACS-purified by CXCR4 and CX3CR1 expression. Quadrant (Q) 2 was not detected (ND).(B) Composite well images of Q1- and Q4-sorted CB. 5 × 10^2^ Q1 and 1 × 10^3^ Q4 sorted cells were seeded per well. Arrowheads indicate individual CFU. Scale bar represents 5 mm.(C) CFU frequency of FACS-purified CB based on chemokine receptor expression. Data points represent *n* independently assayed wells (precise *n* values indicated in the figure). Ø is zero. Q2 was ND. Data are represented as means ± SEM.(D) Sort purities from hPSC-derived hematopoietic cells FACS-purified by CXCR4 and CX3CR1 expression. Q2 was ND.(E) Composite well images of Q1- and Q4-sorted hPSC-derived hematopoietic cells; 2 × 10^4^ sorted cells were seeded per well. Arrowheads indicate individual CFU. Scale bar represents 5 mm.(F) CFU frequency of FACS-purified hPSC-derived hematopoietic cells based on chemokine receptor expression. Data points represent *n* independently assayed wells (precise *n* values indicated in the figure). Q2 was ND. Data are represented as means ± SEM.(G) Transwell assay was conducted with 200 ng/mL CXCL12, or 200 ng/mL CX3CL1, or control (0.001% BSA).(H) Transwell migration was quantified by flow cytometry. Data points represent *n* independently assayed wells (precise *n* values indicated in the figure), pooled from four independently performed experiments. CB used as positive control in every hPSC-HPC experiment. Two-way ANOVA, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001. Data are represented as means ± SEM.

Inducing CXCL12-Dependent CXCR4 Signaling {#sec2.4}
-----------------------------------------

On the basis of a beneficial functional relationship between CXCR4 and somatic HPCs ([@bib4], [@bib23]), we next sought to pharmacologically induce CXCR4 expression by hPSC-HPCs. We tested several pharmacological agents reported to upregulate CXCR4, including cyclic AMP (cAMP) agonists, forskolin and PGE~2~ ([@bib16], [@bib35]), and hormones (Flonase and estrogen; [@bib19], [@bib33]). While these compounds effectively increased the number of CXCR4^+^ CB HPCs, this was not observed from hPSC-HPCs ([Figures 5](#fig5){ref-type="fig"}A, 5B, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B). GSEA pathway analysis demonstrated that networks targeted by these compounds are not equally active ([Figure 5](#fig5){ref-type="fig"}C), supporting our observation of an inability to upregulate CXCR4 by hPSC-HPCs.Figure 5Overcoming Resistance to CXCR4 Expression Enables CXCL12-Dependent Signaling(A) Flow cytometric of CXCR4 within CD34^+^CD45^+^ CB or hPSC-HPCs treated with indicated compounds; see also [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.(B) A summary of total CXCR4^+^CD34^+^CD45^+^ cells from CB and hPSC-HPCs, relative to control (0.01% DMSO or BSA). Data points represent *n* independently assayed wells (precise *n* values indicated in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}), pooled from three independently performed experiments. Data are represented as means ± SEM. Two-way ANOVA, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(C) GSEA analysis of pathways that regulate CXCR4. Samples: CB and H9-HPC; CD34^+^CD45^+^CD38^--^, shown in [Figure 3](#fig3){ref-type="fig"}A. GO, Gene Ontology; NES, normalized enrichment score.(D) Human *CXCR4* was cloned into pHIV-EGFP, which has an internal ribosome entry site (IRES) translation link to GFP (CXCR4^+^). Site-directed mutagenesis of *CXCR4* (N123K) was termed CXCR4(off)^+^. Vector control, expressing GFP, was used in parallel for all experiments.(E) Flow cytometry at 48 hr post transduction on EB day 16, showing comparable hPSC-HPC frequency (CD34^+^CD45^+^), and robust CXCR4^+^GFP^+^ co-expression.(F) Transwell assay was conducted with 200 ng/mL CXCL12 or control (0.001% BSA), and quantified by flow cytometry at 48 hr post transduction on EB day 16. Data points represent *n* independently assayed wells (precise *n* values indicated in the figure), pooled from three independently performed experiments. Two-way ANOVA, ^∗∗∗∗^p \< 0.0001. Data are represented as means ± SEM.(G) Calcium flux transients were monitored in response to CXCL12 (200 ng/mL) in the absence (top row) or presence (bottom row) of CXCR4 inhibitor (AMD3100, 10 μM) at 48 hr post transduction on EB day 16. Ionomycin (10 μM) treatment was used as a positive control to identify live cells.(H and I) The frequency of cells that responded to CXCL12 treatment (transient \>150% of baseline) was quantified in the absence (H) or presence (I) of CXCR4 inhibitor, AMD3100. Data points represent *n* = 4 independently assayed wells per sample, pooled from two independently performed experiments. Ø is zero. Data are represented as means ± SEM.(J) Total CFU counts from transduced hPSC-HPCs seeded into MethoCult ±150 ng/mL CXCL12 at 48 hr post transduction on EB day 16. Data points represent *n* independently assayed wells (precise *n* values indicated in the figure), pooled from three independently performed experiments. Two-way ANOVA, ^∗∗∗∗^p \< 0.0001. Data are represented as means ± SEM.

Therefore, lentiviral ectopic CXCR4 expression was developed and functionally validated ([Figure 5](#fig5){ref-type="fig"}D). We developed an additional vector, which expressed CXCL12-unresponsive CXCR4 (N123K mutation; [@bib48]; termed CXCR4(off)^+^), in order to identify CXCL12-dependent biological effects. A third vector expressed only GFP (vector control). Transduction with our CXCR4 vectors resulted in robust expression of CXCR4, which could also be indirectly monitored using GFP expression ([Figure 5](#fig5){ref-type="fig"}E). Upon transduction, CXCR4^+^ hPSC-derived hematopoietic cells could robustly transmigrate toward CXCL12 in Transwells *in vitro* ([Figure 5](#fig5){ref-type="fig"}F), a classic feature of adult/somatic HPCs ([@bib47]). CXCR4^+^ and CXCR4(off)^+^ hPSC-HPCs expressed similar cell surface CX3CR1 compared with control ([Figure S3](#mmc1){ref-type="supplementary-material"}C), and transduced hPSC-HPCs remained unresponsive to CX3CL1 in chemotaxis assays ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Intracellular calcium signaling was induced by CXCL12 in CXCR4^+^ hPSC-derived hematopoietic cells ([Figure 5](#fig5){ref-type="fig"}G), achieving similar frequencies to that observed in CB ([Figure 5](#fig5){ref-type="fig"}H). The response to CXCL12 was not observed in CXCR4(off) transduced cells and could be inhibited by pre-treatment with the CXCR4 antagonist AMD3100 ([Figures 5](#fig5){ref-type="fig"}G and 5I). CXCR4^+^ hPSC-HPC calcium flux responses were achieved at similar frequencies to CB ([Figure 5](#fig5){ref-type="fig"}H) and were inhibited with the CXCR4 antagonist ([Figures 5](#fig5){ref-type="fig"}G and 5I) ([@bib6]), further demonstrating the functional integration of CXCR4 and the ability to pharmacologically regulate this network within hPSC-HPCs. Additionally, CXCL12 treatment resulted in a CXCR4 dependent 2-fold increase in progenitor capacity ([Figure 5](#fig5){ref-type="fig"}J). The enhancement in CFU potential is in line with a previous report where CXCL12 supplementation in MethoCult increased CB progenitor propagation ([@bib5]). Overall, these data demonstrate that both CXCL12 and CXCR4 are critically involved in hPSC-HPCs, and that lentiviral expression of CXCR4 enables its functional integration into networks supporting biological processes for which hPSC-HPCs were deficient compared with somatic HPC sources.

Enhanced BM Progenitor Retention of CXCR4^+^ hPSC-HPCs {#sec2.5}
------------------------------------------------------

Ectopic CXCR4 has previously been shown to enhance CB engraftment ([@bib23]). We therefore transplanted GFP-tagged CXCR4^+^ hPSC-HPCs *in vivo* and assessed survival and proliferation. Equivalent numbers of hPSC-HPCs transduced with CXCR4 or vector control were injected into large groups of mice (n ≥ 20), in parallel with somatic HPCs ([Figures 6](#fig6){ref-type="fig"}A and 6B). Encouragingly, CXCR4^+^ hPSC-HPCs exhibited enhanced BM retention at the fifth day post transplant ([Figure 6](#fig6){ref-type="fig"}C), and led to a significant increase in phenotypic hPSC-HPC retention overall ([Figures 6](#fig6){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}A) and also enabled CXCR4^+^ hPSC-derived HPCs to migrate to the contralateral femur BM similarly to somatic HPCs ([Figure S4](#mmc1){ref-type="supplementary-material"}B). This finding was specific to the BM, as we did not observe HPCs in the spleen ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4E). Highest frequencies of GFP were observed from the BM of femurs injected with CXCR4^+^ hPSC-HPCs ([Figure S4](#mmc1){ref-type="supplementary-material"}F). The retention of phenotypic hPSC-HPCs was also paralleled with retention of functional progenitors. Impressively, CXCR4 alone was sufficient to rescue progenitor function following transplantation ([Figures 6](#fig6){ref-type="fig"}E, 6F, [S4](#mmc1){ref-type="supplementary-material"}G, and S4H). CFU were manually picked and validated for human origin and lentivirus-based *CXCR4* and *GFP* sequences by PCR ([Figures 6](#fig6){ref-type="fig"}G and 6H). We ascertained a loss of erythroid progenitors from CXCR4^+^ hPSC-HPCs *in vivo* ([Figure S4](#mmc1){ref-type="supplementary-material"}G), consistent with previous reports of HPCs derived from non-human primate *M. nemestrina*-induced PSCs ([@bib17]). CFU retention, measured as a fraction of CFU injected, was equivalent between somatic and CXCR4^+^ hPSC-derived HPCs, and significantly higher than control hPSC-HPCs ([Figure 6](#fig6){ref-type="fig"}I). Unfortunately, CXCR4 was not sufficient to confer sustained engraftment tested at 4 weeks ([Figures 6](#fig6){ref-type="fig"}J--6L). This lack of prolonged hematopoietic reconstitution is possibly due to the silencing of CXCR4 vector (loss of GFP) over time ([Figure S4](#mmc1){ref-type="supplementary-material"}I). Our results suggest the importance of identifying hPSC-HPCs that exhibit dynamic auto-regulation of the CXCR4 pathway in response to extracellular stimuli similar to adult/somatic HPCs.Figure 6CXCR4 Rescues Transplantation Deficiency of hPSC-HPCs(A) Transplant groups: 5x10^4^ CD34^+^CD45^+^ cells were transplanted from CB^CD34^ and both hPSC-HPC groups (48 hr post transduction, on EB day 16). BM from saline-injected mice were collected at every harvest. *n* numbers represent transplanted mice, pooled from two independently performed experiments with four harvest analyses.(B) Injection fraction phenotyping.(C) Flow cytometry of BM harvested on day 5.(D) Total mCD45^--^hCD45^+^CD34^+^ cells per IF. CXCR4^+^ and vector in purple and black, respectively. CB in inset (red). Data points represent *n* transplanted mice. Two-tailed t test, ^∗∗^p \< 0.01.(E) CFU analysis from harvested BM. Arrowheads indicate individual CFU. Scale bar represents 100 μm.(F) Total human CFU per IF. CXCR4^+^ and vector in purple and black, respectively. CB in inset (red). Each data point represents one mouse. Two-tailed t test, ^∗∗^p \< 0.01.(G) 1--5 colonies (2 ± 2) per transplanted BM samples were picked by micropipette, and the non-colony remainder of the well was kept separately (rest). If no CFU were observed, the entire well was collected (all).(H) CFU were analyzed for human and vector sequences by PCR. Samples from BM harvested on day 5. Each box is one NSG mouse. PCR was completed with one to five colonies (2 ± 2) per sample. Two representative CXCR4^+^ mice are shown, with two (left) and one (right) colony shown. CB PCR was completed with one colony. gen, genomic.; vir., viral; sal., saline.(I) CFU retention per IF as a percentage of input CFU. To assess BM retention separately from cellular proliferation and expansion, only 24 hr retention data for CB shown. Ø is zero. Data are represented as means ± SEM.(J) Flow cytometry of CB and hPSC-HPC transplanted IF, harvested 4 weeks post transplant.(K and L) Human chimerism (hCD45^+^mCD45^--^) and (L) GFP frequency at 4 weeks. Data points represent *n* transplanted mice. Data are represented as means ± SEM.

CXCR4 Networks Are a Feature of Somatic HSC/HPCs {#sec2.6}
------------------------------------------------

To investigate CXCR4 auto-regulation, sustained activation, and network responsiveness, global transcriptome analysis of CXCR4^+^ and CXCR4^--^ hPSC-HPCs (CD34^+^CD45^+^GFP^±^) were compared with somatic and seven TF-hPSC-derived HSC/HPCs with long-term engraftment capacity, three TF- and five TF-expressing hPSC-HPCs with little to no engraftment capacity, and related BM/niche cell types ([Figure 7](#fig7){ref-type="fig"}A). CXCR4^+^ hPSC-HPCs clustered as an intermediate between CXCR4^--^ hPSC-HPCs and somatic HPCs. Furthermore, GSEA identified four independent HSC signatures that were significantly enriched in CXCR4^+^ versus CXCR4^--^ hPSC-HPCs, in addition to other cellular adhesion molecules ([Figures 7](#fig7){ref-type="fig"}B and 7C). Global transcriptome analysis of CXCR4^+^ and CXCR4^--^ hPSC-HPCs revealed genes that may shift hPSC-HPCs closer toward somatic HPC profiles as well as genes that continue to be aberrantly expressed ([Figure 7](#fig7){ref-type="fig"}D, [Table S3](#mmc1){ref-type="supplementary-material"}). We observe classical HSC genes, PROM1 and CD34, and adhesion genes, SELL and ICAM2, remaining highly expressed by somatic HPCs compared with CXCR4^+^ hPSC-HPCs. Interestingly, CXCR4^+^ hPSC-HPCs express equivalent levels of the epigenetic regulator MLLT3 compared with somatic HPCs, whereas CXCR4^--^ continue to lack equivalent MLLT3 expression ([Figure 3](#fig3){ref-type="fig"}F and [Table S3](#mmc1){ref-type="supplementary-material"}). Three-hundred and twenty-five genes remain aberrantly expressed, which include mobilization-inducing MMP9 and epigenetic regulator EZH2, in both CXCR4^+^ and CXCR4^--^ hPSC-HPCs, and prevent complete transcriptional overlap with somatic HPCs. Deeper molecular analysis of the transcriptome was performed using Pearson correlation and scoring pathway expression using normalized enrichment scores (NES) from GSEA analyses where BM HPCs were used as reference ([Figure 7](#fig7){ref-type="fig"}E). CXCR4^+^ hPSC-HPCs were most similar to BM HPCs compared with other hPSC-derived cells (Pearson correlation). However, negative NES of CXCR4 regulatory pathways suggests ectopic CXCR4 did not induce auto-regulation. In contrast, while seven TF hPSC-HSC/HPCs are molecularly distinct from somatic HSCs (Pearson correlation of 0.77, similar to original report of \>0.7; [@bib37]), they appear to overexpress CXCR4-related pathways, using the NES as an indicator. The observation of active CXCR4-related pathways in seven TF hPSC-HSC/HPCs ([@bib37]) and BM/niche cell types suggests that, during *in vivo*-programming, BM may select for hPSC-HSCs and HPCs capable of receiving extracellular cues for survival. This reinforces the hypothesis of CXCR4 signaling as necessary, but not sufficient, to produce hPSC-HSCs and HPCs. To functionally investigate auto-regulation, we treated CXCR4^+^ hPSC-HPCs with several CXCR4-inducing agents ([Figure 7](#fig7){ref-type="fig"}F). Indeed, pathways upstream of CXCR4, such as PGE~2~ and glucocorticoids (flonase) ([@bib16], [@bib19]), were unable to synergize with ectopic CXCR4 ([Figures 7](#fig7){ref-type="fig"}F--7H). However, forskolin, a cAMP agonist, increased total CXCR4^+^ HPCs while total cellular yield was equivalent, suggesting incomplete CXCR4 auto-regulation.Figure 7CXCR4 Auto-regulation as a Target for hPSC-HSC Development(A) Data points in PCA correlation biplot represent the global transcriptome of *n* biological replicates pooled from the following sources of FACS-purified HPCs (CD45^+^CD34^+^CD38^±^); GEO: GSE83719, triangles; GEO: GSE49938, diamonds; GEO: GSE3823 and GSE92778, circles; and GEO: GSE106721, hexagons. Ellipses are 2 SDs.(B and C) Enrichment plots (B) and NES (C) of gene sets identified by GSEA as enriched in CD34^+^CD45^+^CXCR4^+^ hPSC-HPCs versus CD34^+^CD45^+^CXCR4^--^ hPSC-HPCs. Of 3,685 C2 (MSigDB) gene sets, 195 were significantly enriched in CD34^+^CD45^+^CXCR4^+^ hPSC-HPCs at nominal p value \<0.05.(D) ANOVA comparing CXCR4^+^ and CXCR4^--^ hPSC-HPCs with somatic HPCs depicted with Venn diagram.(E) Sample groups described in (A) were assessed at the global level (all genes) using Pearson's correlation coefficient, and within gene sets; see also [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. NES from GSEA of indicated groups (biological replicates, not averaged) compared with BM HPCs. GPCR, G protein-coupled receptor.(F--H) CXCR4^+^ hPSC-HPCs were exposed to CXCR4-inducing compounds for 48 hr; see also [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. CXCR4 staining of CD34^+^CD45^+^ cells (F), and quantification of total CXCR4^+^CD34^+^CD45^+^ (G), and bulk cells (H). Data points represent three independently assayed biological replicates. One-way ANOVA, ^∗∗∗^p\<0.001. Data are represented as means ± SEM.(I) A model of CXCR4 function in hPSC-HPCs.

Discussion {#sec3}
==========

Our study demonstrates that CXCR4 is necessary for early transplantation survival but not sufficient to confer long-term engraftment. We suggest that the loss of CXCR4 leads hPSC-HPCs to revert to CXCR4^--^ characteristics instead of auto-regulating CXCR4 *in situ* ([Figure 7](#fig7){ref-type="fig"}H). Altogether, CXCL12-mediated CXCR4 signaling by hPSC-HPCs promotes progenitor proliferation, survival, migration *in vitro*, and increased BM retention *in vivo*. Progress toward hPSC-HSC long-term engraftment has largely been pursued using ectopic TF expression. In contrast, somatic HSCs receive non-cell-autonomous signals in the BM directing cell fate ([@bib2], [@bib3]), therefore we investigated these cues in the context of hPSC-HPCs. Our findings identified hPSC-HPC transplantation deficiencies, which complements previous reports of limited engraftment at 4 weeks ([@bib17], [@bib26], [@bib29], [@bib32], [@bib44]), while at a much earlier time frame within the first week post transplantation.

Cell-autonomous approaches to produce hPSC-HSC/HPCs have made significant progress using ectopic HSC-specific TFs ([@bib13], [@bib12], [@bib31], [@bib37]). However, all four of these reports required TFs with leukemogenic potential, most prominently *RUNX1* (*AML1*) and *ERG* ([@bib9]). Furthermore, the additional effects of *in vivo* BM programming during multiplexed TF expression appear to support higher chimerism frequencies of hPSC-derived hematopoietic cells and multilineage differentiation potential ([@bib37]). CXCR4 function is critical for BM retention and HSC function ([@bib24], [@bib27], [@bib38]); however, similar to TF expression, it must be tightly regulated. Gain-of-function mutations in CXCR4 are associated with a rare primary immunodeficiency called WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome ([@bib20]). Clinical features include abnormal retention of mature hematopoietic cells in the BM of patients, which suggest constitutive knockin or long-term induced expression systems may be deleterious for promoting balanced multilineage engraftment from hPSC-HPCs. This points to the importance of producing hPSC-HPCs that can auto-regulate CXCR4 activity, without prolonged ectopic expression.

Our study establishes a proof of principle that supporting CXCR4 expression is a viable target not only to enhance progenitor survival and proliferation when exposed to CXCL12 *in vitro* or BM *in vivo* but also to promote a more normal hematopoietic transcriptional shift toward somatic HSCs and HPCs. Independent of ectopic chemokine receptor modulation, several other lines of evidence provide support for required functional connectivity between BM niche and hPSC-HPCs for sustained engraftment. The injection of undifferentiated human PSCs into mice has led to the rare production of hPSC-HSCs isolated from the BM ([@bib39]), when the original cells were injected as heterotopic teratomas. Conversely, once isolated from their niche, somatic HSCs are difficult to propagate *in vitro*, and prolonged culture leads to diminished engraftment potential ([@bib4], [@bib21]). Strikingly, the first clinical report of a pharmacological agent able to expand HSCs *in vitro* involved Notch signaling, which operates in a non-cell-autonomous role in the BM ([@bib11]). Together, these relationships underscore the importance of BM cues for hPSC-HPCs as an unappreciated area of biological interaction that requires further investigation for future clinical applications of human HPCs derived from hPSC sources.

Experimental Procedures {#sec4}
=======================

Somatic Blood Samples {#sec4.1}
---------------------

Informed consent was obtained from full-term umbilical CB and MPB donors with protocols approved by the Research Ethics Board at McMaster University. Human BM was purchased from Lonza (Cedarlane, \#1M-105). Mononuclear cells (MNCs) were recovered by density gradient centrifugation (Ficoll-Paque, GE Healthcare), and red blood cells were lysed using ammonium chloride (StemCell Technologies). Lineage depletion was performed by magnetic cell separation using a lineage antibody kit (StemCell Technologies, \#19309C). Cells were cryopreserved in 10% DMSO in fetal bovine serum (FBS) until use.

Xenotransplantation {#sec4.2}
-------------------

Immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were bred in a barrier facility, and all experimental protocols were approved by the Animal Research Ethics Board of McMaster University. Mouse sex and age were controlled within each experiment, and mice were randomly assigned to experimental groups, which included male and female mice. No statistical method was used to predetermine sample size. Mice were sublethally irradiated (single dose of 315 cGy, 137Cs) 24 hr before transplant. Cells were transplanted by intra-femoral injection as previously described ([@bib44]), at doses described in the figure legends. At harvest, mice were killed and BM from the injected and contralateral femurs were collected separately. Spleens were separately harvested. Lungs were harvested in a subset of experiments. Cells were recovered by mechanical dissociation in IMDM supplemented with 3% FBS (HyClone, Canada), and 1 mM EDTA (Invitrogen). Red blood cells were lysed using ammonium chloride. BM samples were counted and plated for CFU frequency. BM cells from NSG mice injected with saline were used as negative controls for CFU. Phenotyping was analyzed using fluorescence minus one gating. Data points were combined from all independent experiments and outliers were not excluded.

Statistics {#sec4.3}
----------

Data are represented as means ± SEM. Prism (6.0c, GraphPad) software was used for all statistical analyses, and the criterion for statistical significance was p \< 0.05. Statistics are described in figure legends.

For details of all other procedures, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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